
$117 Million
Joint Bookrunner
Follow-On
January 2023

$125 Million
Joint Bookrunner
Follow-On
January 2023

UNDISCLOSED
Exclusive Financial Advisor
Strategic Investment from InTandem Capital Partners
January 2023

Up to CHF 200 MILLION
Exclusive Financial Advisor
Sale to Tandem Diabetes Care, Inc.
Pending

$500 MILLION
Joint Bookrunner
Rule 144A Convertible Senior Notes
December 2022

UNDISCLOSED
Exclusive Financial Advisor
Sale to Intuit
Pending

$60 MILLION
Joint Bookrunner
Follow-On
November 2022

$260 Million + Up to $1.8B in Milestone Payments
Exclusive Financial Advisor
Exclusive Licensing Agreements with Point Biopharma
Pending

$50 MILLION
Joint Bookrunner
Follow-On
November 2022

$575 MILLION
Joint Bookrunner
Follow-On
November 2022

$80 MILLION
Joint Bookrunner
Follow-On
November 2022

$500 MILLION
Joint Bookrunner
Follow-On
December 2022